DALLAS, Texas, June 25, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Puration, Inc. (PURA) (“PURAâ€) the producer of EVERx CBD Sports Water, the leading CBD infused beverage in the sports nutrition market today highlighted the Washington Post article published yesterday on the growing market demand for CBD infused foods and beverages.
“Brands as diverse as Ben &
Jerry’s and Coca-Cola are
chomping at the bit to launch CBD-infused products, and
stores like
Walgreens, Kroger and CVS have vowed to
sell them. More than 1,000 CBD-infused products are now available
online.â€
Management indicates the company has had conversation with more
than one major brand name.
PURA Speculative Buy Recommendation and $0.25 PPS Target
w/Potential to $0.35
Goldman Small Cap Research recently released a new
research report recommending PURA as a Speculative BUY with a
$0.25 PPS Target. Goldman Small Cap Research further
reports that the shares of PURA “have the potential to reach the
$0.35 mark.†The report highlights PURA’s growing EVERx CBD
Sports Water sales and the coming introduction of new beverages as
well as the potential for the company to exceed its 2019 sales
targets through the pending doubling of its production capacity and
through planned acquisitions.
PURA achieved over $1 million in sales in 2018 and is well on its
way toward a targeted $4 million in sales in 2019. PURA is
the sole license of a U.S. Patented Cannabis Extraction Process
owned by Kali-Extracts, Inc. (aka Kali, Inc.) (KALY) (“KALYâ€).
For more information on Puration, visit http://www.purationinc.com
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the
meaning of the Securities Litigation Reform Act. The statements
reflect the Company's current views with respect to future events
that involve risks and uncertainties. Among others, these risks
include the expectation that any of the companies mentioned herein
will achieve significant sales, the failure to meet schedule or
performance requirements of the companies' contracts, the
companies' liquidity position, the companies' ability to obtain new
contracts, the emergence of competitors with greater financial
resources and the impact of competitive pricing. In the light of
these uncertainties, the forward-looking events referred to in this
release might not occur. These statements have not been evaluated
by the Food and Drug Administration. These products are not
intended to diagnose, treat, cure, or prevent any
disease.
Contact:
Puration, Inc.
Brian Shibley,
[email protected]
(800) 861-1350